Literature DB >> 6538014

Long-term treatment with pergolide: decreased efficacy with time.

A N Lieberman, M Goldstein, M Leibowitz, G Gopinathan, A Neophytides, E Hiesiger, J Nelson, R Walker.   

Abstract

We studied the effect of pergolide (combined with levodopa) in 17 patients with Parkinson's disease, including 15 with "wearing off" or on-off phenomena, who had been taking pergolide for at least 2 years. Mean duration of the study was 27.8 months. All 17 patients improved initially, but the improvement later faded. Mean disability score, which decreased initially by 60% (significant), was decreased only by 20% after 2 years (not significant). Wearing off and on-off phenomena, which improved initially, became prominent again. Four patients lost all the improvement, nine patients lost much of the improvement, and four maintained much of the improvement. Mean dose of pergolide was 2.2 mg (range, 0.8 to 5.0 mg).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538014     DOI: 10.1212/wnl.34.2.223

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Authors:  A Markham; P Benfield
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 6.497

Review 3.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.